Search

Aim. To evaluate the associations of abdominal obesity (AO), adipokines and premature coronary artery disease (CAD) in young people for a deeper understanding of the pathogenesis of atherosclerotic diseases.Material and methods. A total of 1457 people were examined, including 653 (44,8%) men. Mean age was 36,7±6,0 years. Premature CAD was detected in 46 people, while 4 following subgroups were formed (138 people in total): with CAD and AO; with CAD, without AO; control groups by age and sex: without CAD, with AO; without CAD, without AO.Results. Premature CAD in young people is associated with an increase in non-high-density lipoprotein cholesterol (non-HDL-C). Univariate analysis found that the probability of CAD increased by 1% with an increase in adiponectin level, and by 0,2% with an increase of 1 ng/ml in resistin level. Multivariate regression analysis, including sex, age, waist circumference, non-HD-C, adiponectin, and resistin, significant associations were obtained for non-HDL-C and adiponectin. With AO, the CAD probability increased by 0,6% with an increase in plasminogen activator inhibitor-1 level (PAI-1). However, when non-HDL-C was included in the model, significance for this biomarker was not achieved.Conclusion. In young people, CAD is associated with increased levels of non-HDL cholesterol, adiponectin, resistin and PAI-1. Independent associations with premature CAD were obtained only for adiponectin, which makes this marker promising for study in young people.

The article discusses a new approach to assessing cardiovascular risk in clinical practice, presented in the European guidelines 2021. Two novel risk charts (SCORE2 and SCORE2-OP) have been proposed that have undergone significant revision and require significant changes in primary care practice. It has been suggested that in modern conditions their practical introduction is premature, since the healthcare system is not ready for renewal. Therefore, time is needed to adapt it to the practical healthcare conditions and to revise the medical screening protocols, which will require financial costs. The implementation of these recommendations should be taken responsibly so as not to harm the existing system of preventive care.

The paper reviews the relevance of various types of cholesterol as factors of cardiovascular risks. According to recent recommendations, apart from the routinely evaluated low-density lipoprotein cholesterol (LDL-H), clinicians now look at non-HDL (high-density lipoprotein) cholesterol. The paper questions, whether there is enough clinical and scientific evidence to change priorities in the lipid assessment of cardiovascular risk: measurement and monitoring of non-HDL cholesterol vs. routine lipid markers - LDL cholesterol and plasma HDL cholesterol.